Dr. Vincent Tuohy is an immunologist at the Lerner Research Institute at the Cleveland Clinic - the second best hospital in the United States. Prior to working at the Cleveland Clinic, he was awarded by the National Multiple Sclerosis Society, the Society for Experimental Neuropathology and the National Institute of Neurological Disorders and Stroke at the National Institutes of Health for his research efforts on the immune response occurring in human multiple sclerosis, a prototypic human autoimmune disease caused by an autoimmune attack against the patient’s own central nervous system.
After recruitment to the Cleveland Clinic in 1989, Dr. Tuohy continued targeting the immune response against several tissue-specific self-proteins thereby developing autoimmune rodent models for a number of other human diseases. In 2002, Dr. Tuohy began to focus his research on the immune response to self-proteins that are over-expressed in adult-onset cancers but are no longer expressed with age in normal tissues. He proposed that these "retired" proteins may serve as useful vaccine targets for preventing cancers associated with aging, such as breast cancer and ovarian cancer.
Dr. Tuohy conducted trials in mice that develop breast cancer by vaccinating against a breast-specific protein that is often expressed in triple negative breast cancer (TNBC), the most aggressive and lethal form of breast cancer. The results were astounding, with 100% of the vaccinated mice being protected from breast cancer. The vaccine not only inhibited growth of established breast tumors, but also prevented new tumors from forming and did so without damaging normal tissues. Since the publication of this study, Dr. Tuohy has been raising funds in order to conduct human trials.
Information derived from The Lerner Research Institute of the Cleveland Clinic.
This video, created by the Cleveland Clinic, highlights the work of Dr. Tuohy.